HepaTx
hepatx.com
Actively hiring
Cell & Gene Therapy
Regenerative Medicine
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Y Combinator
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Y Combinator Similar startupsby what they do, their industry and backers
Juvena Therapeutics is a clinical-stage biotechnology company engineering proteins that human stem cells naturally secrete into…
Syntax Bio is a synthetic biology company programming the next generation of stem cell-derived therapies and organoids.
Cellusion develops regenerative medicine therapies using induced pluripotent stem (iPS) cells focused on treating corneal endothelial…
Cellino is a Massachusetts biotechnology company founded in 2017. It automates stem cell manufacturing with laser editing, imaging and…
Constellation® is an automated cell therapy manufacturing platform that enables scalable, flexible production without therapy redevelopment…
Acorn is a personalized regenerative medicine company, helping people preserve their own cells to prepare for the future of cell-based…
Overview
Invest on Wefunder ABOUT HEPATX STRATEGY TEAM CAREERS SCIENCE MEDIA CONTACT US Optimal Go-to-Market Strategy We are on a mission to completely change the face of liver disease treatment with our breakthrough stem cell-based therapy as an alternative to transplant.
News
HepaTx Enters Collaboration with Mayo Clinic to Advance Cell Therapy Technology for Liver Disease to Clinical Trials
/PRNewswire/ -- HepaTx, a biotechnology company specializing in regenerative medicine, has entered into a license agreement with Mayo Clinic to advance...
Read more
Report
Hepatx Enters Collaboration With Mayo Clinic To Advance Cell Therapy Technology For Liver Disease To Clinical Trials
Hepatx Enters Collaboration With Mayo Clinic To Advance Cell Therapy Technology For Liver Disease To Clinical Trials.PALO ALTO, Calif., Sept. 10, 2024 /PRNewswire/ -- HepaTx, a biotechnology company specializing in regenerative medicine, has entered into
Read more
Report
Dr. Mack C. Mitchell Joins HepaTx Clinical Advisory Board
HepaTx, a biotechnology company focused on cell therapy for liver diseases, is thrilled to announce the appointment of Dr. Mack C. Mitchell to its Clinical Advisory Board. With his extensive gastroenterology and clinical pharmacology expertise, Dr. Mitche
Read more
Report
HepaTx Welcomes Transplant Hepatologist Julio Gutierrez, MD to the Clinical Advisory Board
HepaTx, a pre-clinical stage biotechnology company dedicated to the development of transformative therapies for liver diseases, announced today that Julio Gutierrez, MD has joined their Clinical Advisory Board.
Read more
Report
Professor Mark Thursz Joins the Hepatx Scientific Advisory Board to Advance Liver Disease Treatment
Imperial College London's Professor of Hepatology, Mark Thursz, has been appointed to the Scientific Advisory Board of HepaTx (the SAB), a biotechnology company focused on cell therapy liver diseases
Read more
Report
Pro access
Upgrade to see all 20 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.